AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21474637 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 34
Study 21474637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 34
Study 18061276 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (PhT)
Number of subjects: 141
Study 18061276 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐term psychodynamic supportive psychotherapy (SPSP)
Number of subjects: 141
Study 16390499 — intervention group
Group type: EXPERIMENTAL
Intervention: Testoderm TTS body patch (5 mg/day, n = 20)
Number of subjects: 39
Study 16390499 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (n = 19)
Number of subjects: 39
Study 16390499 — intervention group
Group type: EXPERIMENTAL
Intervention: Testoderm TTS body patch (5 mg/day, n = 20) and Placebo patch (n = 19)
Number of subjects: 39
Study 14606111 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlicin prevention group
Number of subjects: 70
Study 14606111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (low dosage) prevention group
Number of subjects: 70
Study 14606111 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 10929446 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram alfacalcidol plus 5000 mg calcium (group A)
Number of subjects: 85
Study 10929446 — intervention group
Group type: COMPARATOR
Intervention: 1000 IU vitamin D plus 500 mg calcium (group B)
Number of subjects: 85
Study 8761391 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA enhancement
Number of subjects: 25
Study 1563531 — intervention group
Group type: EXPERIMENTAL
Intervention: tolrestat 200 mg once daily for 6 months
Number of subjects: 190
Study 1563531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 4003919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (theophylline + salbutamol)
Number of subjects: 25
Study 4003919 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 25
Study 4003919 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 25
Study 4003919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 4003919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 25
Study 31978429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICS)
Number of subjects: 463
Study 31978429 — intervention group
Group type: COMPARATOR
Intervention: Low-dose inhaled corticosteroids (ICS)
Number of subjects: 463
Study 29991209 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-fractionated Hypericum perforatum (M-Hp)
Number of subjects: 0
Study 29991209 — intervention group
Group type: COMPARATOR
Intervention: Conventional Hypericum perforatum (C-Hp)
Number of subjects: 0
Study 27565426 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrodia cinnamomea (AC) 20 ml twice daily for 30 days
Number of subjects: 37
Study 27565426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 25438877 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reward for each accepted antipsychotic medication depot (M4M)
Number of subjects: 168
Study 25438877 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual without financial rewards
Number of subjects: 168
Study 22612986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheotomy tube diameter 6.5 mm
Number of subjects: 10
Study 22612986 — intervention group
Group type: COMPARATOR
Intervention: Tracheotomy tube diameter 8 mm
Number of subjects: 10
Study 20537455 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRs calculated using the 4‐variable isotope‐dilution mass spectrometry (IDMS)‐traceable MDRD Study equation
Number of subjects: 1995
Study 20537455 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRs calculated using the CKD‐EPI SCysC equation
Number of subjects: 1995
Study 20537455 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRs calculated using the CKD‐EPI SCr‐SCysC equation
Number of subjects: 1995
Study 20537455 — intervention group
Group type: EXPERIMENTAL
Intervention: Average of 3 consistent mGFRs
Number of subjects: 1995
Study 20537455 — intervention group
Group type: EXPERIMENTAL
Intervention: Average of 2 consistent mGFRs
Number of subjects: 1995
Study 20537455 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reference mGFR
Number of subjects: 1995
Study 17296986 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging in patients with neuropsychologic deficits
Number of subjects: 12
Study 17296986 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 12
Study 15691253 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregularity Index parameters for malignant melanomas
Number of subjects: 188
Study 15691253 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregularity Index parameters for predicting disease status
Number of subjects: 188
Study 15691253 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant melanoma with irregular border
Number of subjects: 188
Study 11809987 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental shuttle walking test (SWT) after combined nebulised salbutamol/ipratropium bromide
Number of subjects: 82
Study 11809987 — intervention group
Group type: COMPARATOR
Intervention: Incremental shuttle walking test (SWT) in controls without airflow limitation
Number of subjects: 82
Study 11809987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living index (NEADL)
Number of subjects: 82
Study 11809987 — intervention group
Group type: EXPERIMENTAL
Intervention: London Handicap score (LHS)
Number of subjects: 82
Study 11809987 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 1 second (FEV1)
Number of subjects: 82
Study 10609815 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 655
Study 10609815 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac SR 75 mg twice daily
Number of subjects: 655
Study 7856783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (smokeless tobacco cessation intervention)
Number of subjects: 518
Study 2048706 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 31
Study 2048706 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 31
Study 2048706 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 31
Study 2048706 — intervention group
Group type: COMPARATOR
Intervention: Control (preoperative data)
Number of subjects: 31
Study 2048706 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (C)
Number of subjects: 31
Study 7196564 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation treatment
Number of subjects: 0
Study 7196564 — intervention group
Group type: EXPERIMENTAL
Intervention: DRS xenon technique
Number of subjects: 0
Study 7196564 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 31527919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools of the Mind (Tools)
Number of subjects: 351
Study 31527919 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional classes)
Number of subjects: 351
Study 29446445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micro g/kg
Number of subjects: 42
Study 29446445 — intervention group
Group type: COMPARATOR
Intervention: Biosimilar filgrastim 10 micro g/kg
Number of subjects: 42
Study 27098429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with BCNU (or busulfan) and thiotepa followed by autologous stem cell transplantation (HCT‐ASCT)
Number of subjects: 250
Study 27098429 — intervention group
Group type: COMPARATOR
Intervention: Conventional‐dose immuno chemotherapy with rituximab 375 mg/m(2) (d0), dexamethasone 40 mg/d (d1‐3), etoposide 100 mg/m(2)/d (d1‐3), ifosfamide 1500 mg/m(2)/d (d1‐3) and carboplatin 300 mg/m(2) (d1) (R‐DeVIC)
Number of subjects: 250
Study 27098429 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT‐ASCT
Number of subjects: 250
Study 27098429 — intervention group
Group type: COMPARATOR
Intervention: R‐DeVIC
Number of subjects: 250
Study 24465425 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg daily)
Number of subjects: 133
Study 24465425 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 133
Study 24465425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 23234253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led personalised care intervention
Number of subjects: 0
Study 20632503 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament-retained mobile-bearing prosthesis (group A)
Number of subjects: 73
Study 20632503 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior stabilized fixed-bearing prosthesis (group B)
Number of subjects: 73
Study 20632503 — intervention group
Group type: COMPARATOR
Intervention: Posterior cruciate ligament-retained mobile-bearing prosthesis (group C)
Number of subjects: 73
Study 20632503 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 73
Study 17066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk factor model for predicting reading achievement
Number of subjects: 494
Study 17066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk factor model for predicting mathematics achievement
Number of subjects: 494
Study 16107306 — intervention group
Group type: EXPERIMENTAL
Intervention: aceclofenac-loaded soft capsule (100mg)
Number of subjects: 14
Study 16107306 — intervention group
Group type: COMPARATOR
Intervention: conventional aceclofenac tablet (100mg)
Number of subjects: 14
Study 11877640 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy (LA)
Number of subjects: 129
Study 11877640 — intervention group
Group type: COMPARATOR
Intervention: Open Appendectomy (OA)
Number of subjects: 129
Study 10624546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (12 weeks treatment)
Number of subjects: 0
Study 10624546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 weeks treatment)
Number of subjects: 0
Study 8963396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotripsy plus ursodeoxycholic acid (UDCA)
Number of subjects: 143
Study 8963396 — intervention group
Group type: COMPARATOR
Intervention: Lithotripsy alone
Number of subjects: 143
Study 8963396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study 1971647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 45
Study 1971647 — intervention group
Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 45
Study 7003573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release papaverine preparation
Number of subjects: 14
Study 30156056 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg, once daily)
Number of subjects: 84
Study 30156056 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1,000 mg, twice daily)
Number of subjects: 84
Study 30156056 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 84
Study 27566295 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 294
Study 27566295 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (AAD)
Number of subjects: 294
Study 27566295 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment
Number of subjects: 294
Study 25885258 — intervention group
Group type: COMPARATOR
Intervention: Wrist acceleration measurement
Number of subjects: 61
Study 25885258 — intervention group
Group type: COMPARATOR
Intervention: Vertical axis chest frequency measurement
Number of subjects: 61
Study 25885258 — intervention group
Group type: COMPARATOR
Intervention: Wrist sensor data analysis for gestures
Number of subjects: 61
Study 25885258 — intervention group
Group type: COMPARATOR
Intervention: Wrist sensor data analysis for walking
Number of subjects: 61
Study 25885258 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist acceleration measurement pre- and post-treatment
Number of subjects: 61
Study 25885258 — intervention group
Group type: COMPARATOR
Intervention: Amplitude measurement
Number of subjects: 61
Study 25885258 — intervention group
Group type: COMPARATOR
Intervention: Frequency measurement
Number of subjects: 61
Study 24052565 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g pralidoxime over 20 min, followed by an infusion of 0.5 g/h
Number of subjects: 0
Study 24052565 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g pralidoxime chloride
Number of subjects: 0
Study 24052565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20406523 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate iCBT with e-mail support over 3 months
Number of subjects: 76
Study 20406523 — intervention group
Group type: COMPARATOR
Intervention: Waiting list/delayed treatment control (WL/DTC)
Number of subjects: 76
Study 19734776 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.05, 0.1, or 0.2 mg/kg/d
Number of subjects: 205
Study 19734776 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.2 mg/kg/d
Number of subjects: 205
Study 19734776 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.1 mg/kg/d
Number of subjects: 205
Study 19734776 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.1 and 0.2 mg/kg/d
Number of subjects: 205
Study 19734776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 16711546 — intervention group
Group type: EXPERIMENTAL
Intervention: Metilprednisolone aceponate 0.1%
Number of subjects: 34
Study 16711546 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05%
Number of subjects: 34
Study 11184219 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural helpers intervention with health and skill-building education over 18 months
Number of subjects: 104
Study 11184219 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural helpers intervention
Number of subjects: 104
Study 8880048 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol controlled release 150 mg (TCR150)
Number of subjects: 20
Study 8880048 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol controlled release 100 mg (TCR100)
Number of subjects: 20
Study 8880048 — intervention group
Group type: COMPARATOR
Intervention: tramadol standard formulation (T100)
Number of subjects: 20
Study 2051734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day‐1)
Number of subjects: 40
Study 2051734 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (1st month 10 mg; 2nd month 20 mg; 3rd month 40 mg day‐1)
Number of subjects: 40
Study 6825993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (60% calories as fat, 20% as carbohydrate)
Number of subjects: 8
Study 6825993 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (20% calories as fat, 60% as carbohydrate)
Number of subjects: 8
Study 31495201 — intervention group
Group type: EXPERIMENTAL
Intervention: BL-8040 + G-CSF
Number of subjects: 0
Study 31495201 — intervention group
Group type: COMPARATOR
Intervention: Placebo + G-CSF
Number of subjects: 0
Study 29215511 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 70
Study 29215511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 70
Study 26598449 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 42
Study 26598449 — intervention group
Group type: COMPARATOR
Intervention: Standard semi-structured assessment interview
Number of subjects: 42
Study 25230734 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt‐1/PlGF ratio
Number of subjects: 1000
Study 22349746 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol 15 mg/kg
Number of subjects: 60
Study 22349746 — intervention group
Group type: COMPARATOR
Intervention: IV saline infusion 1.5 mL/kg
Number of subjects: 60
Study 20124113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling) for 3 months
Number of subjects: 0
Study 20124113 — intervention group
Group type: COMPARATOR
Intervention: Playing table football (control group) for 3 months
Number of subjects: 0
Study 20124113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling)
Number of subjects: 0
Study 20124113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and nonexercise schizophrenia group
Number of subjects: 0
Study 17338766 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > or =30 kg/m(2))
Number of subjects: 476
Study 17338766 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients (BMI <30 kg/m(2))
Number of subjects: 476
Study 15960429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g alcohol/kg body weight (females: 10% less)
Number of subjects: 24
Study 15960429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g alcohol/kg body weight (females: 10% less)
Number of subjects: 24
Study 15960429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12014907 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 12014907 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 0
Study 10533993 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental handling
Number of subjects: 38
Study 10533993 — intervention group
Group type: COMPARATOR
Intervention: Traditional handling
Number of subjects: 38
Study 7576897 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural Support Nappy (PSN)
Number of subjects: 60
Study 7576897 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nappy (Control)
Number of subjects: 60
Study 31791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for Physician-Assisted Suicide (PAS)
Number of subjects: 369
Study 31791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that respect for autonomy justifies PAS
Number of subjects: 369
Study 31791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent to prescribe or support PAS if legal
Number of subjects: 369
Study 31791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory palliative care consultation and independent assessments from two physicians
Number of subjects: 369
Study 31791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding vulnerable populations
Number of subjects: 369
Study 31535102 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation without bone grafting (test group)
Number of subjects: 12
Study 31535102 — intervention group
Group type: COMPARATOR
Intervention: Osteotome sinus floor elevation with bone grafting (control group)
Number of subjects: 12
Study 28972192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 0.3 mg·kg‐1·d‐1
Number of subjects: 331
Study 28972192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 0.6 mg·kg‐1·d‐1
Number of subjects: 331
Study 28972192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 28972192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (low-dose)
Number of subjects: 331
Study 28972192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (high-dose)
Number of subjects: 331
Study 26939334 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection at Zusanli (ST 36) combined with electroacupuncture (EA) at Hegu (LI 4) and Sanyinjiao (SP 6)
Number of subjects: 84
Study 26939334 — intervention group
Group type: COMPARATOR
Intervention: Routine respiratory instruction
Number of subjects: 84
Study 26939334 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection and EA
Number of subjects: 84
Study 22068465 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon α (3 million to 6 million units) administered intramuscularly 3 times a week for 1 year
Number of subjects: 100
Study 22068465 — intervention group
Group type: COMPARATOR
Intervention: Follow-up observation until recurrence or metastasis occurred
Number of subjects: 100
Study 21288972 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid preload
Number of subjects: 60
Study 21288972 — intervention group
Group type: COMPARATOR
Intervention: Colloid preload
Number of subjects: 60
Study 19494743 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glue (fibrin glue composite)
Number of subjects: 67
Study 19494743 — intervention group
Group type: COMPARATOR
Intervention: Control group (instrumented posterolateral lumbar fusion with artificial bone expander and laminectomy autograft)
Number of subjects: 67
Study 19494743 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 19494743 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glue
Number of subjects: 67
Study 19494743 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glue and Control group
Number of subjects: 67
Study 17583373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone alone (P)
Number of subjects: 120
Study 17583373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus azathioprine (P/A)
Number of subjects: 120
Study 17583373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus mycophenolate mofetil (P/MM)
Number of subjects: 120
Study 17583373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus intravenous cyclophosphamide pulse therapy (P/PC)
Number of subjects: 120
Study 17583373 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic groups (P/A, P/MM, P/PC)
Number of subjects: 120
Study 15024666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC) - 200 mg of ascorbic acid twice a day for 14 days prior to exercise and for 3 days after exercise
Number of subjects: 14
Study 15024666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) - identical capsules containing 200 mg lactose
Number of subjects: 14
Study 15024666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC)
Number of subjects: 14
Study 15024666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study 11216954 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 114